Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Companion Diagnostics and Biomarkers

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

Andrew Stone, Mark J. Cowley, Fatima Valdes-Mora, Rachael A. McCloy, C. Marcelo Sergio, David Gallego-Ortega, C. Elizabeth Caldon, Christopher J. Ormandy, Andrew V. Biankin, Julia M.W. Gee, Robert I. Nicholson, Cristin G. Print, Susan J. Clark and Elizabeth A. Musgrove
Andrew Stone
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Cowley
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fatima Valdes-Mora
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachael A. McCloy
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Marcelo Sergio
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Gallego-Ortega
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Elizabeth Caldon
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Ormandy
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew V. Biankin
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia M.W. Gee
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert I. Nicholson
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristin G. Print
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan J. Clark
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Musgrove
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0012 Published September 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2013 to March 2021

AbstractFull-text HTMLPDF
Total368023263533

Cited By

Article Information

Volume 12, Issue 9, pp. 1874-1885

DOI 
https://doi.org/10.1158/1535-7163.MCT-13-0012
PubMed 
23861345

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received January 7, 2013
  • Revision received June 21, 2013
  • Accepted July 10, 2013
  • Published first July 16, 2013.

Article Versions

  • Previous version (July 16, 2013 - 14:20).
  • Previous version (August 28, 2013 - 13:07).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2013 American Association for Cancer Research.

Author Information

  1. Andrew Stone1,
  2. Mark J. Cowley1,
  3. Fatima Valdes-Mora1,2,
  4. Rachael A. McCloy1,
  5. C. Marcelo Sergio1,
  6. David Gallego-Ortega1,2,
  7. C. Elizabeth Caldon1,2,
  8. Christopher J. Ormandy1,2,
  9. Andrew V. Biankin1,2,
  10. Julia M.W. Gee3,
  11. Robert I. Nicholson3,
  12. Cristin G. Print4,
  13. Susan J. Clark1,2, and
  14. Elizabeth A. Musgrove1,2
  1. Authors' Affiliations: 1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
  1. Corresponding Author:
    Andrew Stone, Garvan Institute of Medical Research, L9 TKCC, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. Phone: 61-424618528; Fax: 61-293555869; E-mail: a.stone{at}garvan.org.au
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 12 (9)
September 2013
Volume 12, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Andrew Stone, Mark J. Cowley, Fatima Valdes-Mora, Rachael A. McCloy, C. Marcelo Sergio, David Gallego-Ortega, C. Elizabeth Caldon, Christopher J. Ormandy, Andrew V. Biankin, Julia M.W. Gee, Robert I. Nicholson, Cristin G. Print, Susan J. Clark and Elizabeth A. Musgrove
Mol Cancer Ther September 1 2013 (12) (9) 1874-1885; DOI: 10.1158/1535-7163.MCT-13-0012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Andrew Stone, Mark J. Cowley, Fatima Valdes-Mora, Rachael A. McCloy, C. Marcelo Sergio, David Gallego-Ortega, C. Elizabeth Caldon, Christopher J. Ormandy, Andrew V. Biankin, Julia M.W. Gee, Robert I. Nicholson, Cristin G. Print, Susan J. Clark and Elizabeth A. Musgrove
Mol Cancer Ther September 1 2013 (12) (9) 1874-1885; DOI: 10.1158/1535-7163.MCT-13-0012
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • UNG Determines Lung Cancer Sensitivity to Pemetrexed
  • LMTK3 and Gastric Cancer
Show more Companion Diagnostics and Biomarkers
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement